CELU Stock - Celularity Inc.
Unlock GoAI Insights for CELU
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $54.22M | $22.77M | $17.98M | $21.34M | $14.28M |
| Gross Profit | $39.23M | $6.75M | $-1,690,000 | $11.68M | $9.35M |
| Gross Margin | 72.4% | 29.7% | -9.4% | 54.8% | 65.5% |
| Operating Income | $-38,358,000 | $-192,287,000 | $-25,600,000 | $-109,059,000 | $-151,925,000 |
| Net Income | $-57,892,000 | $-196,295,000 | $14.19M | $-100,118,000 | $-208,233,000 |
| Net Margin | -106.8% | -862.0% | 79.0% | -469.3% | -1458.4% |
| EPS | $-2.64 | $-11.02 | $1.01 | $-14.93 | $-113.06 |
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 30th 2023 | Morgan Stanley | Downgrade | Underweight | $1← $5 |
| December 22nd 2022 | Oppenheimer | Downgrade | Perform | - |
| June 22nd 2022 | H.C. Wainwright | Initiation | Buy | $15 |
| April 6th 2022 | Truist | Downgrade | Hold | $10 |
Earnings History & Surprises
CELUEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-1.50 | $-0.88 | +41.3% | ✓ BEAT |
Q3 2025 | Aug 29, 2025 | — | $-0.84 | — | — |
Q2 2025 | May 8, 2025 | $-1.50 | $-0.59 | +60.7% | ✓ BEAT |
Q4 2024 | Dec 6, 2024 | $-1.40 | $-0.73 | +47.9% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-1.40 | $-0.30 | +78.6% | ✓ BEAT |
Q3 2024 | Sep 27, 2024 | — | $3.40 | — | — |
Q3 2024 | Jul 31, 2024 | — | $0.54 | — | — |
Q1 2024 | Jan 2, 2024 | $-0.04 | $-0.60 | -1566.7% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.30 | $3.40 | +1233.3% | ✓ BEAT |
Q2 2023 | May 22, 2023 | $-2.40 | $-2.20 | +8.3% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.25 | $-0.03 | +88.0% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-2.60 | $0.30 | +111.5% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-2.60 | $0.30 | +111.5% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-2.30 | $-4.80 | -108.7% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-2.90 | $-0.30 | +89.7% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-2.90 | $4.00 | +237.9% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.16 | $-2.69 | -1581.2% | ✗ MISS |
Q2 2021 | May 24, 2021 | $-0.14 | $2.48 | +1871.4% | ✓ BEAT |
Q1 2021 | Mar 4, 2021 | — | $0.64 | — | — |
Latest News
FDA Issues Warning Letter To Celularity Over Interfyl Marketing Claims; Co Says No Impact On Manufacturing Or Shipments
📉 NegativeCelularity Enters Strategic Partnership With DefEYE Including An Exclusive License And Pricing Agreement Tied To Celularity's In-Kind Investment In DefEYE's $12M Series Seed Preferred Equity Funding Round
📈 PositiveCelularity Files For 6M Series A Convertible Preferred Stock, Raising Up To $6.67M In Private Placement With Warrants
➖ NeutralCelularity Announces Publication Of Its Phase 2 Study On PDA-002 Demonstrating Safety And Efficacy In Treating Complex Diabetic Wounds
📈 PositiveWBB Securities Upgrades Celularity to Buy, Maintains Price Target to $6
📈 PositiveCelularity Receives Nasdaq Notification Regarding Form 10-Q
📉 NegativeWBB Securities Initiates Coverage On Celularity with Speculative Buy Rating, Announces Price Target of $6
📈 PositiveFrequently Asked Questions about CELU
What is CELU's current stock price?
What is the analyst price target for CELU?
What sector is Celularity Inc. in?
What is CELU's market cap?
Does CELU pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CELU for comparison